A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 as a Single-Agent Treatment in Subjects with HER2- Advanced Breast Cancer or in Combination with Trastuzumab in Subjects with HER2+ Advanced Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2015
At a glance
- Drugs CNF 2024; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Biogen
- 01 Dec 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2011 Planned end date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.